for real wealth effect.
Over the past few decades biotechnology – sometimes described
as the oldest profession in the world – has evolved into a modern
technology without which medical progress would be
scarcely imaginable. Modern biotechnology plays a crucial role
both in the elucidation of the molecular causes of disease and in
the development of new diagnostic methods and better targeted
These developments have led to the birth of a new economic sector,
the biotech industry, associated mostly with small start-up
companies. For their part, the more established healthcare companies
have also been employing these modern techniques,
known collectively as biotechnology, successfully for many
years. By studying the molecular foundations of diseases they
have developed more specific ways of combating diseases than
ever before. This new knowledge permits novel approaches to
treatment, with new classes of drug – biopharmaceuticals – attacking
previously unknown targets. Increasing attention is also
being paid to differences between individual patients, with the
result that in the case of many diseases the goal of knowing in
advance whether and how a particular treatment will work in a
given patient is now within reach. For some patients this dream
has already become reality.
Diagnosis and treatment are thus becoming increasingly intertwined.
When a disease, rather than being diagnosed on the basis
of more or less vague signs and symptoms, can be detected
on the basis of molecular information, the possibility of successful
treatment depends largely on what diagnostic techniques
are available. To the healthcare industry this represents a major
development in that diagnosis and treatment are growing ever
closer together, with clear benefits for companies that possess
competence in both these areas. To patients, progress in medical
biotechnology means one thing above all: more specific, safer
and more successful treatment of their illnesses. To the healthcare
industry it represents both an op
The traders are only interested in what happens in the next nano second of trading.
I want to own the future. Organovo's technology will be an integral part of the biotech industry.
It is obvious how desperate it is trashing and bashing 24/7.
time to put it on ignore. ta ta
time to move on.
Dying patients could someday receive a 3D-printed organ made from their own cells rather than wait on long lists for the short supply of organ transplants. Such a futuristic dream remains far from reality, but university labs and private companies have already taken the first careful steps by using 3D-printing technology to build tiny chunks of organs.
Regenerative medicine has already implanted lab-grown skin, tracheas and bladders into patients body parts grown slowly through a combination of artificial scaffolds and living human cells. By comparison, 3D-printing technology offers both greater speed and computer-guided precision in printing living cells layer by layer to make replacement skin, body parts and perhaps eventually organs such as hearts, livers and kidneys.
Beyond organ implants
For now, bioprinting pioneers hope to make use of even the smallest 3D-printed organs. Atala's lab recently received U.S. Department of Defense funding for a collaborative project aimed at printing tiny hearts, livers and kidneys to form a connected "body on a chip" ideal for testing possible drugs and the effects of diseases or chemical warfare agents on the human body.
Organovo has already started developing a 3D-printed liver model for testing the safety and efficacy of drugs. The startup company is also creating cancerous versions of living tissue models for testing cancer drugs.
The constantly rising cost of healthcare affects us all. Oganovo's technology can help to greatly reduce those costs. It will be widely accepted as a method for lowering the cost of drug research and discovery. IT will also provide tissue/organs/arteries etc at much lower costs then are presently incurred.
This is just the start.
Animal Testing and Cosmetics
May 31, 1999; Updated April 5, 2006
The Food and Drug Administration (FDA) is responsible for assuring that cosmetics are safe and properly labeled. This mission is accomplished through enforcement of the Federal Food, Drug, and Cosmetic Act1 (FD&C Act), related statutes, and regulations promulgated under these laws.
The FD&C Act does not specifically require the use of animals in testing cosmetics for safety, nor does the Act subject cosmetics to FDA premarket approval. However, the agency has consistently advised cosmetic manufacturers to employ whatever testing is appropriate and effective for substantiating the safety of their products. It remains the responsibility of the manufacturer to substantiate the safety of both ingredients and finished cosmetic products prior to marketing.
Animal testing by manufacturers seeking to market new products may be used to establish product safety. In some cases, after considering available alternatives, companies may determine that animal testing is necessary to assure the safety of a product or ingredient. FDA supports and adheres to the provisions of applicable laws, regulations, and policies governing animal testing, including the Animal Welfare Act 2and the Public Health Service Policy of Humane Care and Use of Laboratory Animals3. Moreover, in all cases where animal testing is used, FDA advocates that research and testing derive the maximum amount of useful scientific information from the minimum number of animals and employ the most humane methods available within the limits of scientific capability.
We also believe that prior to use of animals, consideration should be given to the use of scientifically valid alternative methods to whole-animal testing. In 1997, FDA joined with thirteen other Federal agencies in forming the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). ICCVAM and its supporting center, the National Toxicology Program Interagency Center